Citadel Advisors
ZNTL icon

Citadel Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Citadel Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.2K Buy
+11,200
New +$28.9K ﹤0.01% 12613
2025
Q4 		– Sell
-33,000
Closed -$49.8K – 14303
2025
Q3 		$49.8K Buy
33,000
+11,000
+50% +$16.5K ﹤0.01% 12215
2025
Q2 		$25.5K Buy
22,000
+10,400
+90% +$13.7K ﹤0.01% 12045
2025
Q1 		$18.4K Buy
11,600
+4,700
+68% +$10.1K ﹤0.01% 13205
2024
Q4 		$20.9K Sell
6,900
-49,700
-88% -$163K ﹤0.01% 13155
2024
Q3 		$208K Buy
56,600
+50,000
+758% +$182K ﹤0.01% 10060
2024
Q2 		$27K Buy
6,600
+4,300
+187% +$48K ﹤0.01% 12369
2024
Q1 		$36.2K Sell
2,300
-2,900
-56% -$39.9K ﹤0.01% 12496
2023
Q4 		$78.8K Sell
5,200
-6,100
-54% -$89K ﹤0.01% 11241
2023
Q3 		$227K Buy
11,300
+10,200
+927% +$259K ﹤0.01% 9670
2023
Q2 		$31K Buy
1,100
+700
+175% +$16.8K ﹤0.01% 12315
2023
Q1 		$6.88K Sell
400
-800
-67% -$16.2K ﹤0.01% 13774
2022
Q4 		$24.2K Buy
+1,200
New +$25.8K ﹤0.01% 12978
2021
Q4 		– Sell
-6,300
Closed -$420K – 14917
2021
Q3 		$420K Buy
6,300
+800
+15% +$46.1K ﹤0.01% 10296
2021
Q2 		$293K Buy
+5,500
New +$295K ﹤0.01% 11327

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's ZNTL Position: Q1 2026 in Review

Citadel Advisors reduced its Zentalis Pharmaceuticals (ZNTL) stake by 12% in Q1 2026, selling an estimated $600K and leaving 1,732,083 shares worth $4.05M. The position accounts for ﹤0.01% of the portfolio, ranked #4691.

Citadel Advisors first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $78.1M in Q4 2020. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Citadel Advisors held 1,732,083 shares of Zentalis Pharmaceuticals worth $4.05M as of Q1 2026.
  • Citadel Advisors sold 232,172 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $600K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4691 holding.
  • Citadel Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Zentalis Pharmaceuticals position peaked at $78.1M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.